OBJECTIVE: Given the fact that Mullerian Inhibiting Substance (MIS) causes complex remodeling of the urogenital ridge and regression of the Mullerian ducts during male embryonic development, we examined whether MIS could affect similar cell properties such as migration and invasion that could contribute ultimately to micro-metastasis of cancers arising from Mullerian tissues. MIS receptor expressing cell lines found to be invasive and migratory in vivo are examined in an in vivo assay that is cost-effective. METHODS: We designed in vitro and in vivo experiments to determine if MIS inhibited the movement of cancer lines IGROV-1, HEp3, MDA-MB-231, and HT1080 in cell culture invasion/migration chamber assays and in chick embryo metastasis assays. RESULTS: MIS, at concentrations below those that inhibit cell proliferation, blocked in vitro invasion and in vivo migration of epithelial cancer cells that express the MIS receptor. CONCLUSIONS: While our laboratory has previously established MIS as an inhibitor of cancer cell proliferation using in vitro assays and in vivo xenografts, we now show that MIS can also inhibit in vivo tumor migration.
OBJECTIVE: Given the fact that Mullerian Inhibiting Substance (MIS) causes complex remodeling of the urogenital ridge and regression of the Mullerian ducts during male embryonic development, we examined whether MIS could affect similar cell properties such as migration and invasion that could contribute ultimately to micro-metastasis of cancers arising from Mullerian tissues. MIS receptor expressing cell lines found to be invasive and migratory in vivo are examined in an in vivo assay that is cost-effective. METHODS: We designed in vitro and in vivo experiments to determine if MIS inhibited the movement of cancer lines IGROV-1, HEp3, MDA-MB-231, and HT1080 in cell culture invasion/migration chamber assays and in chick embryo metastasis assays. RESULTS:MIS, at concentrations below those that inhibit cell proliferation, blocked in vitro invasion and in vivo migration of epithelial cancer cells that express the MIS receptor. CONCLUSIONS: While our laboratory has previously established MIS as an inhibitor of cancer cell proliferation using in vitro assays and in vivo xenografts, we now show that MIS can also inhibit in vivo tumor migration.
Authors: Maria Loscertales; Amanda J Mikels; Jimmy Kuang-Hsein Hu; Patricia K Donahoe; Drucilla J Roberts Journal: Development Date: 2008-02-27 Impact factor: 6.868
Authors: L Gouédard; Y G Chen; L Thevenet; C Racine; S Borie; I Lamarre; N Josso; J Massague; N di Clemente Journal: J Biol Chem Date: 2000-09-08 Impact factor: 5.157
Authors: P T Masiakos; D T MacLaughlin; S Maheswaran; J Teixeira; A F Fuller; P C Shah; D J Kehas; M K Kenneally; D M Dombkowski; T U Ha; F I Preffer; P K Donahoe Journal: Clin Cancer Res Date: 1999-11 Impact factor: 12.531
Authors: Xiaolong Wei; David Dombkowski; Katia Meirelles; Rafael Pieretti-Vanmarcke; Paul P Szotek; Henry L Chang; Frederic I Preffer; Peter R Mueller; Jose Teixeira; David T MacLaughlin; Patricia K Donahoe Journal: Proc Natl Acad Sci U S A Date: 2010-10-15 Impact factor: 11.205
Authors: N di Clemente; C Wilson; E Faure; L Boussin; P Carmillo; R Tizard; J Y Picard; B Vigier; N Josso; R Cate Journal: Mol Endocrinol Date: 1994-08
Authors: Jae Yen Song; Keun Young Chen; Sue Yeon Kim; Mee Ran Kim; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; David T MacLaughlin; Jang Heub Kim Journal: Int J Oncol Date: 2009-06 Impact factor: 5.650
Authors: Akihiro Fujino; Nelson A Arango; Yong Zhan; Thomas F Manganaro; Xianlin Li; David T MacLaughlin; Patricia K Donahoe Journal: Dev Biol Date: 2008-11-05 Impact factor: 3.582
Authors: W M Baarends; M J van Helmond; M Post; P J van der Schoot; J W Hoogerbrugge; J P de Winter; J T Uilenbroek; B Karels; L G Wilming; J H Meijers Journal: Development Date: 1994-01 Impact factor: 6.868
Authors: Tim N Beck; Vladislav A Korobeynikov; Alexander E Kudinov; Rachel Georgopoulos; Nehal R Solanki; Magda Andrews-Hoke; Timothy M Kistner; David Pépin; Patricia K Donahoe; Emmanuelle Nicolas; Margret B Einarson; Yan Zhou; Yanis Boumber; David A Proia; Ilya G Serebriiskii; Erica A Golemis Journal: Cell Rep Date: 2016-07-07 Impact factor: 9.423
Authors: Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan Journal: Int J Cancer Date: 2017-10-04 Impact factor: 7.396
Authors: Xiu Xiu Jiang; Kai Hong Xu; Jun Yan Ma; Yong Hong Tian; Xiao Yan Guo; Jun Lin; Rui Jin Wu Journal: Oncol Lett Date: 2012-05-30 Impact factor: 2.967